Cam Gallagher

Cam S.
Gallagher was the founder of Nerveda LLC, founded in 2007, serving as Managing Director.
Mr. Gallagher was the founder of DioGenix, Inc., founded in 2008, serving as Chairman.
Mr. Gallagher is the founder of Zentalis Pharmaceuticals, Inc., founded in 2014, serving as President, CFO, Treasurer & Director in 2024.
Current jobs include President, Chief Executive Officer & Director at Alessa Therapeutics, Inc. since 2024; Chairman at Opus Genetics, Inc. since 2019; Director at selectION, Inc. since 2018; Director at Immusoft Corp.
since 2022; Venture Partner at Mesa Verde Ventures LLC; and General Partner at Velosity Capital since 2021.
Former jobs include Marketing Director at CV Therapeutics, Inc. from 1992 to 2004; Director & Chief Business Officer at RetroSense Therapeutics LLC from 2014 to 2016; Independent Director at Sorrento Therapeutics, Inc. from 2012 to 2014; Director at Rexahn Pharmaceuticals, Inc. from 2019 to 2020; Director & Vice President-Corporate Development at Oncternal Oncology, Inc.; Director at OcuSub, Inc. from 2019 to 2020; Director at VelosBio, Inc. from 2017 to 2020; Director at Healios KK from 2022 to 2023; Director & Head-Corporate Development at Oncternal Therapeutics, Inc. from 2016 to 2019; Executive Director at Ray Therapeutics, Inc. from 2021 to 2023; Sales Management & Marketing Executive at Dura Pharmaceuticals, Inc. in 2004; Vice President-Marketing at Verus Pharmaceuticals, Inc. from 2004 to 2007; Senior Vice President-Business Development at Neurelis, Inc.; Chief Business Officer at jCyte, Inc. from 2019 to 2020; and Chief Business Officer at Kalyra Pharmaceuticals, Inc. from 2013 to 2024.
Education includes an undergraduate degree from The Ohio University in 1992 and an MBA from the University of San Diego in 1997.